6. Parkinson disease Clinical trials / Disease details

Clinical trials : 2,298 / Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

6 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03576638 (ClinicalTrials.gov)	July 2018	25/6/2018	Study to Assess Pharmacokinetics of Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Parkinson's Disease Patients	An Open Label Phase 2 Study to Assess the Pharmacokinetics of the Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Patients With Parkinson's Disease	Parkinson Disease	Drug: Accordion Pill Carbidopa/Levodopa;Drug: Sinemet CR 25Mg-100Mg Extended-Release Tablet	Intec Pharma Ltd.	NULL	Unknown status	30 Years	N/A	All	12	Phase 2	NULL
2	NCT03111485 (ClinicalTrials.gov)	May 24, 2017	28/3/2017	Effect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson's Disease	Effect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson's Disease	Parkinson's Disease;Obstructive Sleep Apnea	Drug: Sinemet CR;Drug: Placebo oral capsule	McGill University Health Centre/Research Institute of the McGill University Health Centre	Weston Brain Institute	Recruiting	18 Years	N/A	All	42	Phase 4	Canada
3	NCT01470859 (ClinicalTrials.gov)	December 2011	9/11/2011	The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Disease	a Pilot Follow-up Study of Investigating the Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Chinese Patients With Early Parkinson's Disease	Idiopathic Parkinson's Disease	Drug: pramipexole;Drug: Sinemet CR	Huashan Hospital	Boehringer Ingelheim	Completed	30 Years	75 Years	All	30	N/A	China
4	EUCTR2007-005033-11-DE (EUCTR)	27/03/2008	04/01/2008	A Comparison Of The Safety And Bioavailability Of Modified-Release Formulations Of Levodopa-Carbidopa In Subjects With Parkinson’s Disease	A Comparison Of The Safety And Bioavailability Of Modified-Release Formulations Of Levodopa-Carbidopa In Subjects With Parkinson’s Disease	Patients with Parkinson's Disease	Product Name: Levodopa -Carbidopa Multilayer Extended Release Tablet Product Code: Levodopa -Carbidopa XL tablet (M) INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa Trade Name: Sinemet® CR Product Name: Sinemet CR INN or Proposed INN: Levodopa INN or Proposed INN: Carbidopa	CombinatoRx, Inc	NULL	Not Recruiting			Female: yes Male: yes			Germany
5	EUCTR2005-001032-72-CZ (EUCTR)	16/02/2006	12/01/2006	A 39-week randomized, double-blind, parallel group, multicenter study to evaluate the effect of fixed dose Stalevo 100 (t.i.d.) vs. immediate release carbidopa/levodopa (t.i.d.) in Parkinson's disease patients requiring levodopa. - First Step	A 39-week randomized, double-blind, parallel group, multicenter study to evaluate the effect of fixed dose Stalevo 100 (t.i.d.) vs. immediate release carbidopa/levodopa (t.i.d.) in Parkinson's disease patients requiring levodopa. - First Step		Trade Name: Stalevo 100 mg/25 mg / 200 mg Product Code: ELC200 Trade Name: SINEMET CR Product Name: SINEMET CR	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	424		Portugal;Czech Republic;Italy
6	NCT00174239 (ClinicalTrials.gov)	July 2004	9/9/2005	Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease.	A Double-Blind, Randomized, Comparative Study of Cabaser and Sinemet CR For The Treatment Of Nocturnal Disability In Levodopa -Treated Parkinson's Disease Patients.	Parkinson Disease	Drug: cabergoline;Drug: controlled-release levodopa / carbidopa	Pfizer	NULL	Terminated	18 Years	80 Years	Both	220	Phase 4	Australia;Italy;Spain;United Kingdom